伴隨診斷服務的合作與授權協議（2010-2026 年）

Companion Diagnostic Collaboration and Licensing Deals 2010-2026

出版日期: 2026年05月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

伴隨診斷領域的權威基準測試。

伴隨診斷領域的合作是由診斷技術和治療藥物開發的整合所驅動的，其合約結構反映了共同開發策略、監管協調以及精準醫療的方法。

本報告對超過 560 項伴隨診斷合作和許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對伴隨診斷領域的合約實際結構進行了精確的闡述。

類似交易的可靠基準
對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
定義切合實際的市場參數
清楚洞察基於技術類型、與治療領域的契合度以及合作夥伴概況的合約條款差異。
支持基於證據的評估和合約結構確定。
讓內部討論基於實際交易數據，而不是僅基於假設。
了解主要公司的交易方式
在以精準醫療為驅動、以協作開發為重點的環境中，可視化合作夥伴的行為模式和重複出現的合約結構。
它旨在用於實際的業務拓展和策略制定。

本報告廣泛用於以下用途：

建立診斷和治療夥伴關係並進行基準測試
在清晰的市場環境下準備談判
評估聯合開發和許可機會
利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

超過 560 項與伴隨診斷相關的合作與許可協議。
財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
可全文搜尋的合約目錄（按公司、技術和治療領域）
可直接查閱向美國證券交易委員會提交的合約和原始文件。
合約趨勢、重大交易和活躍合約方分析。
可靠的、依證的伴隨診斷參考資料。
本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為在伴隨診斷領域建立、談判和評估夥伴關係提供了可靠的、依證證據的資源。

合約目錄
合約目錄：依公司分類的伴隨診斷合約（A-Z）
合約目錄：依合約類型分類的伴隨診斷合約
合約目錄：按治療領域分類的伴隨診斷合約
合約類型的定義
關於 Biopharma Research Ltd.
關於當前合作夥伴關係
關於現行協議
Current Partnering 最新報告列表

簡介目錄

Product Code: CP2106

The definitive benchmark for companion diagnostic dealmaking

Companion diagnostic partnering is driven by the integration of diagnostics with therapeutic development, with deal structures reflecting co-development strategies, regulatory alignment, and precision medicine approaches.

This report provides a comprehensive and structured analysis of 560+ companion diagnostic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how companion diagnostic deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by technology type, therapeutic alignment, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a precision medicine-driven and co-development-focused landscape
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark diagnostic-therapeutic partnerships
Prepare for negotiations with well-defined market context
Evaluate co-development and licensing opportunities
Support internal strategy with robust, defensible data
What's included
560+ companion diagnostic collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and therapeutic alignment)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for companion diagnostic dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how companion diagnostic partnerships are structured, negotiated, and valued.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
- 2.7.1 Companion diagnostic deals headline values
- 2.7.2 Companion diagnostic deal upfront payments
- 2.7.3 Companion diagnostic deal milestone payments
- 2.7.4 Companion diagnostic royalty rates